Literature DB >> 18561140

A novel polymorphic purine complex at the 1.5 kb upstream region of the human caveolin-1 gene and risk of Alzheimer's disease; extra-short alleles and accumulated allele homozygosity.

Y Heshmati1, A Mirabzadeh, G Feizzade, M Gilanipour, M R Etminan, H R Khoram Khorshid, K Kamali, M Fakhri, N Moghimi, H Najmabadi, M Ohadi.   

Abstract

Crucial interaction of caveolin-1 (CAV1) with beta- and gamma-secretases, and aberrant expression of the gene encoding this protein in Alzheimer's disease (AD) support a role for CAV1 in the pathophysiology of this disease. We report a novel polymorphic purine complex stretching approximately 150 bp of genomic DNA at the 1.5 kb upstream region of the human CAV1 gene, alleles and genotypes of which are associated with sporadic late-onset AD. Extra-short alleles were observed in the case group that were absent in the control subjects. Remarkably, 63% of these alleles were observed to be homozygous in length, forming 23.7% of the homozygote length compartment in the AD cases (chi(2) = 19.08, df = 1, P < 0.000007). Increased homozygosity for length was also observed at this region in the Alzheimer's cases, for the allele lengths shared by the case and control groups [(chi(2) = 30.75, df = 1, P < 0.0000000, OR = 4.54, CI 95% (2.56-8.3)]. This region contains GGAA and GAAA motifs, the consensus binding sites for the Ets and IRF family transcription factors, respectively, and is highly conserved in distantly related non-human primates in respect with location and motif sequence. The effect of this complex sequence on the expression of CAV1, and the related mechanisms in the pathophysiology of AD remain to be clarified. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18561140     DOI: 10.1002/ajmg.b.30805

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  5 in total

1.  CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.

Authors:  Danxin Wang; Xiaochun Sun; Yan Gong; Brian E Gawronski; Taimour Y Langaee; Mohamed Hossam A Shahin; Sherief I Khalifa; Julie A Johnson
Journal:  Drug Metab Dispos       Date:  2012-01-30       Impact factor: 3.922

2.  Caveolin-1 deletion reduces early brain injury after experimental intracerebral hemorrhage.

Authors:  Che-Feng Chang; Shu-Fen Chen; Tzong-Shyuan Lee; Hung-Fu Lee; Szu-Fu Chen; Song-Kun Shyue
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

3.  Biased homozygous haplotypes across the human caveolin 1 upstream purine complex in Parkinson's disease.

Authors:  Hossein Darvish; Abolfazl Heidari; Saman Hosseinkhani; Abolfazl Movafagh; Ali Khaligh; Javad Jamshidi; Hamid Noorollahi-Moghaddam; Hamid Reza Heidari-Rostami; Siamak Karkheiran; Gholam-Ali Shahidi; Mansoureh Togha; Seyed Mohammad Hassan Paknejad; Hossein Ashrafian; Siamak Abdi; Saghar Ghasemi Firouzabadi; Seyed Hamid Jamaldini; Mina Ohadi
Journal:  J Mol Neurosci       Date:  2013-05-04       Impact factor: 3.444

4.  Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease.

Authors:  Laith N Al-Eitan; Ayah Y Almasri; Sahar O Al-Habahbeh
Journal:  Pharmgenomics Pers Med       Date:  2019-03-21

5.  Association between upstream purine complexes of human caveolin-1 gene and schizophrenia in qazvin province of iran.

Authors:  Reza Najafipour; Abolfazl Heidari; Safar Ali Alizadeh; Hannaneh Ghafelebashi; Zahra Rashvand; Amir Javadi; Mohammad Moradi; Hosein Afshar
Journal:  Iran Red Crescent Med J       Date:  2014-11-30       Impact factor: 0.611

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.